statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

See the rest of the story here.

thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...

Cytokinetics presents additional 48-week data from FOREST-HCM study

Treatment with Aficamten for 48 Weeks is Associated with Improvements in Clinical Efficacy Endpoints, NYHA Class and Cardiac Biomarkers, Structure and FunctionSOUTH SAN FRANCISCO, Calif., April 05...

Cytokinetics Presents Additional 48-Week Data From FOREST-HCM, the Open Label Extension Clinical Study of Aficamten, at The American College of Cardiology 73  Annual Scientific Session

Shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) have earned a consensus rating of "Moderate Buy" from the fifteen brokerages that are currently covering the stock, MarketBeat...

Brokerages Set Cytokinetics, Incorporated (NASDAQ:CYTK) PT at $79.33

$100 Invested In Cytokinetics 5 Years Ago Would Be Worth This Much Today

SOUTH SAN FRANCISCO, Calif., April 02, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on March 29, 2024 it granted stock options to purchase an aggregate of...

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Cytokinetics, Incorporated: Buyout Speculation Persists...

Cytokinetics, Incorporated: Buyout Speculation Persists

SOUTH SAN FRANCISCO, Calif., April 01, 2024 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I. Blum, President and Chief Executive Officer, is scheduled to...

Cytokinetics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

In the latest look at stocks ordered by largest market capitalization, Russell 3000 component Cytokinetics Inc (CYTK) was identified as having a larger market cap than the smaller end of the S&P 500...

Cytokinetics Moves Up In Market Cap Rank, Passing Paramount Global

This price move could be a signal that CYTK may fall back below the higher band and head toward the middle band. Traders may consider selling the stock, shorting the stock, or exploring put options...

Cytokinetics (CYTK, $71.15) price may drop as it broke higher Bollinger Band on Mar 26, 2024

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

Volume	781,163.00
52-Wk High	$110.25
52-Wk Low	$25.98

CYTK Cytokinetics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals